

Form 144

FORM 144

NOTICE OF PROPOSED SALE OF SECURITIES  
PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933

## 144: Filer Information

Filer CIK 0001462808  
Filer CCC XXXXXXXXX  
Is this a LIVE or TEST Filing?  LIVE  TEST

### Submission Contact Information

Name  
Phone  
E-Mail Address

## 144: Issuer Information

Name of Issuer Revolution Medicines, Inc.  
SEC File Number 001-39219

Address of Issuer

700 SAGINAW DR  
REDWOOD CITY  
CALIFORNIA  
94063

Phone 650-481-6801

Name of Person for Whose Account the Securities are To Be Sold Kelsey Stephen Michael

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer Officer

## 144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common Stock	ETRADE Financial Corporation 3 Edison Drive Alpharetta GA 30005	4604	206857.72	168219391	12/16/2024	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

## 144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from	Is this	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
--------------------	-------------------	-----------------------------------	---------------------	---------	---------------------	-------------------------------	-----------------	---------------------

			Whom Acquired	a Gift?		
Common Stock	03/04/2021	Restricted stock unit grant	Issuer	<input type="checkbox"/>	479	03/04/2021 Services rendered
Common Stock	03/01/2022	Restricted stock unit grant	Issuer	<input type="checkbox"/>	1229	03/01/2022 Services rendered
Common Stock	03/01/2023	Restricted stock unit grant	Issuer	<input type="checkbox"/>	1268	03/01/2023 Services rendered
Common Stock	03/01/2024	Restricted Stock Unit	Issuer	<input type="checkbox"/>	1628	03/01/2024 Services rendered

\* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

## 144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Stephen Michael Kelsey c/o Revolution Medicines, Inc. 700 Saginaw Drive Redwood City CA 94063	Common Stock	09/16/2024	4665	206124.42
Stephen Michael Kelsey c/o Revolution Medicines, Inc. 700 Saginaw Drive Redwood City CA 94063	Common Stock	10/14/2024	14056	694102.15
Stephen Michael Kelsey c/o Revolution Medicines, Inc. 700 Saginaw Drive Redwood City CA 94063	Common Stock	10/14/2024	2610	130702.28
Stephen Michael Kelsey c/o Revolution Medicines, Inc. 700 Saginaw Drive Redwood City CA 94063	Common Stock	11/13/2024	13778	805814.60
Stephen Michael Kelsey c/o Revolution Medicines, Inc. 700 Saginaw Drive Redwood City CA 94063	Common Stock	11/13/2024	2888	171694.20

## 144: Remarks and Signature

Remarks The transaction dated October 14, 2024, involving 14,056 shares, reflects the weighted average price, with sale prices ranging from \$48.95 to \$49.94. The transaction dated October 14, 2024, involving 2,610 shares, reflects the weighted average price, with sale prices ranging from \$49.95 to \$50.27. The transaction dated November 13, 2024, involving 13,778 shares, reflects the weighted average price, with sale prices ranging from \$58.13 to \$59.12. The transaction dated November 13, 2024, involving 2,888 shares, reflects the weighted average price, with sale prices ranging from \$59.13 to \$59.86.

Date of Notice 12/16/2024

Date of Plan Adoption or Giving of Instruction, If 05/31/2023

Relying on  
Rule 10b5-1

**ATTENTION:**

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature      Jack Anders, as Attorney-in-Fact for Stephen Michael Kelsey

***ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)***